TargetTri - identifying side effects of new drugs sooner
It can take up to 10 years and cost many billions to develop a new drug. Often only to find during the last phase that the active ingredients are not sufficiently effective or have undesirable side effects. We’ve developed the web-based platform TargetTri, which enables you to identify the risks of undesirable effects at an early stage. This significantly reduces the chance of failure.
Developing a new drug starts by choosing the protein in the human body that should respond to the drug. This is called the drug target. This protein will inhibit a disease process or stimulate other biological processes.
Collecting and interpreting data
Based on literature and available data, we’ve long been making reports to assess the risks of new drug targets. Now we’ve perfected this process. We not only collect relevant data, but also interpret that data to produce a well-founded risk analysis. Artificial intelligence (AI) and machine learning play an essential role in this process.
Different areas of expertise
We deploy a wide range of expertise that makes the TargetTri platform unique. With text and data mining, we collect and structure the right information. Our toxicologists are familiar with the latest scientific developments and relevant sources. We use systems biology to study interactions between proteins and their effects. The field of Computational Chemistry also makes important contributions.
More efficient, effective, and affordable
By bringing forward the analysis of possible side effects, TargetTri makes the drug discovery pipeline far more efficient, effective, and affordable. Pharmaceutical companies gain insight into the effectiveness and risks of the selected drug targets from the very start of the drug development process. Various pharmaceutical companies participated in the development of TargetTri and are now using it in their research.
Interested?
Are you interested in the activities of TargetTri? Or would you like to invest in commercialising this platform? Reach out to us and get in touch with Eddy Zwier.
Contact us
-
Eddy Zwier
-
Standplaats:Den Haag - New Babylon
-
Telefoon:+31 6 46 84 73 09
-
Email:Email Eddy
-
LinkedIn:Eddy on LinkedIn
-
Get inspired
Functional microbiome analysis
TNO has a wide range of available tools to increase understanding of the impact and interaction of the microbiome on human health. Learn more.
PK Studies AMS
With TNO’s microtracer expertise, drug development becomes a streamlined and targeted process.
Target safety assessment
Our unique set of assessments and web-based target triaging platform TargetTri, can help to make informed decision making easy with transparent, knowledge-driven expert views on target efficacy, safety liabilities, and risk mitigation.
Advanced microtracer studies
A drug’s ADME and ADR's are often difficult to predict. At TNO we have developed in vitro and ex vivo platforms that can help to make this easier.
In-vitro platforms
To better estimate the efficacy of drug candidates, TNO is developing various translational models that help to accurately predict events in the human body.
